Organization and Description of Business - Additional Information (Details) $ in Thousands	1 Months Ended		3 Months Ended		6 Months Ended
	Jul. 31, 2021 USD ($)	Jun. 30, 2021 USD ($)	Mar. 31, 2021 shares	Jun. 30, 2020 shares	Jun. 30, 2021 USD ($) segment shares	Jun. 30, 2020 USD ($)	Dec. 31, 2020 USD ($)
Organization and Description of Business [Line Item]
Accumulated deficit		$ 316,760			$ 316,760		$ 260,723
Cash and cash equivalents		64,456			64,456		$ 28,122
Working capital		72,300			72,300
Aggregate offering price		200,000			200,000
Proceeds from issuance of common stock					60,351	$ 472
Proceeds from issuance of common stock, deducting underwriting discounts, commissions, and other offering costs					60,200
Aggregate offering price, remaining		132,600			$ 132,600
Reportable segment | segment					1
Common Stock
Organization and Description of Business [Line Item]
Issuance of common stock in public offering, net (in shares) | shares			18,400,000	80,523	18,400,000
SFJ Pharmaceuticals X, Ltd.
Organization and Description of Business [Line Item]
Proceeds from partnership contribution					$ 12,500
Equity Distribution Agreement with Citigroup Global Markets Inc. and William Blair & Company, L.L.C.
Organization and Description of Business [Line Item]
Aggregate offering price		60,000			60,000
Proceeds from issuance of common stock					2,900
Aggregate offering price, remaining		57,000			$ 57,000
Equity Distribution Agreement with Citigroup Global Markets Inc. and William Blair & Company, L.L.C. | Common Stock
Organization and Description of Business [Line Item]
Issuance of common stock in public offering, net (in shares) | shares					561,848
Alfasigma S.p.A.
Organization and Description of Business [Line Item]
Upfront payment from sublicense agreement		$ 20,000
Alfasigma S.p.A. | Subsequent Event [Member]
Organization and Description of Business [Line Item]
Upfront payment from sublicense agreement	$ 20,000